Stock 0MGB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Genmab A/S London S.E.

Equities

0MGB

DK0010272202

Market Closed - London S.E.
Other stock markets
 10:55:00 2024-07-03 am EDT 		5-day change 1st Jan Change
1,730 DKK +1.24% Intraday chart for Genmab A/S -3.93% -19.25%
Jun. 28 Would you like some more inflation? Our Logo
Jun. 28 Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU
MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
CI
Genmab Closes DKK3.5 Billion Share Buyback Early
MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
MT
Genmab Wins US Approval for Follicular Lymphoma Treatment
MT
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY
CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
CI
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study
MT
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin
CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial
CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial
MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma
CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab
CI
Genmab A/S Reaffirms Financial Guidance for 2024
CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.
CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress
CI
GENMAB : A good start to 2024; guidance unchanged
Alphavalue
Genmab Posts Q1 Net Profit Surge; Revenue Jumps
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. 0MGB Stock
  5. News Genmab A/S
  6. Highlights